TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: calf vascular resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Prescription errors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resolution of primary CPL symptom
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardioversion success rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postprocedural pain
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Energy required for cardioversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Employment functioning
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: stroke/systemic embolic events
Endpoint domain: Mortality/survival
Primary endpoint: Sustained pharmacological closure of HsPDA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptoms of necrotizing enterocolitis (NEC)
Endpoint domain: Adverse events/effects
Primary endpoint: Need for surgical ligation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of individuals who classified CTGs correctly
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Erythema and pigmentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Quality-adjusted life-year gained
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Investigator-assessed redness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: performance on the 0.8-km run
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: performance on the single-legged hop
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: performance on the long jump
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fecal calprotectin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Performance status improvement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: WBF measured with DXA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Jaeger reading vision
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: symptomatic reherniation
Endpoint domain: Adverse events/effects
Primary endpoint: device- or procedure-related serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Median Annualized Bleeding Rate (ABR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Graves' Ophthalmopathy (GO) improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC of glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Appetite control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urethral opening pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incontinence episodes
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Brunnstrom Stage improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Foot-tapping improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Strength of knee extension/flexion improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Appearance score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Occlusal comfort score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Improved abdominal pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improved bloating
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improved stool frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C(max) of melphalan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC of melphalan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total clearance of melphalan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cultural identity
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Self-reported healthful eating and physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to virologic suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: median reduction in internal carotid artery flow following L‐NMMA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: performance on the CRTT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Responsiveness to ITB
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: infant crying and fussing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of fluoroscopy
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Physical well-being (PWB) scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Time to worsening in PWB scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to NMES
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: hyperemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Self-Esteem scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mood improvement (feeling of depression)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: β‐catenin expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: indices of endothelial cell activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Chemokine expression levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric mean of the absolute bioavailability of fluticasone furoate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects mostly or very satisfied with treatment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: amount of resorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cumulative 12-month mortality
Endpoint domain: Mortality/survival
Primary endpoint: number of vascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Maximum plasma concentration (Cmax,ss)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Provision of smoking-cessation counseling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of HIV-associated TB
Endpoint domain: Mortality/survival
Primary endpoint: plasma levels of von Willebrand factor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: plasma levels of soluble CD40 ligand
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Patient tolerance for upper endoscopy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Intrarater reliability of the modified digital inclinometer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Validity of the modified digital inclinometer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean absolute difference in FEV1 at 90 minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: postoperative complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: resection margin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: blood nutrition status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Clinical Global Impression-Improvement score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Quality of Life Enjoyment and Satisfaction Questionnaire score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Social and Occupational Functioning Scale score
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Communication about sexuality with parents
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: GCS somatic subscore
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: visual analog scale score for back pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oswestry Low Back Pain Disability Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: complication and reoperation rates
Endpoint domain: Adverse events/effects
Primary endpoint: functional performance staging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in daily spasm frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FSH and LH rise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Sensitivity and specificity for diagnosing late onset infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: prevention of stretch-back
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional outcomes (FAOS scores)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: left atrial systolic function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: left atrial reservoir function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: total costs per treated patient
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Cerebral desaturation (SjvO2 values below 50%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Difference in therapeutic classification of activated coagulation time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Rate of first breastfeeding experience
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Average score of perceived self‐efficacy in breastfeeding
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Restoration survival rate after 24 months
Endpoint domain: Mortality/survival
Primary endpoint: Pulp exposure
Endpoint domain: Adverse events/effects
Primary endpoint: Restorative failure
Endpoint domain: Adverse events/effects
Primary endpoint: Radiation dose reduction in the breast
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Provider acceptance of pharmacist-provided recommendations
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient satisfaction with videoconferencing MTM services
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Effective analgesia (visual analog scale <30 mm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average duration of analgesia (119 min)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall ratings of interviews
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Elbow flexors muscle thickness (MT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Elbow flexors peak torque (PT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: A1C improvements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Stent migration rate
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of incisional hernias
Endpoint domain: Adverse events/effects
Primary endpoint: ROSC (Return of Spontaneous Circulation)
Endpoint domain: Mortality/survival
Primary endpoint: Survival for 6 months
Endpoint domain: Mortality/survival
Primary endpoint: Bone Mineral Density (BMD) at the femoral neck
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total femur Bone Mineral Density (BMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: local progression-free survival
Endpoint domain: Mortality/survival
Primary endpoint: ABCA1-mediated cholesterol efflux
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: tolerance of MDCO-216
Endpoint domain: Adverse events/effects
Primary endpoint: subjective vigilance and effectiveness assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cartilage degradation as measured by CTX‐II
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone degradation as measured by CTX‐I
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pulmonary artery temperature of 33±1 degrees C
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: No major complications occurred
Endpoint domain: Adverse events/effects
Primary endpoint: Passive rewarming >35 degrees C accomplished within 7 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: body fat content
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ankle-brachial pressure index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: resting thrombin generation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Increase in CD4+ cell counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Decrease in HIV-1 RNA titers in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: late postprandial hypoglycemic rates
Endpoint domain: Adverse events/effects
Primary endpoint: time until first flatus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: time until bowel movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: colonic transit time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Decrease in mean blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: ratings of teaching effectiveness
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: ghrelin activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: NPY levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Liver volume after 1 month
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Regeneration index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum levels of hepatocyte growth factor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of achieving competency
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Development of ESCAP
Endpoint domain: Mortality/survival
Primary endpoint: Colonic filling
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Small intestine transit time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Frequency of intracranial hemorrhage
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of grade >=2 acneiform rash
Endpoint domain: Adverse events/effects
Primary endpoint: Overall survival at 1, 3, and 5 years
Endpoint domain: Mortality/survival
Primary endpoint: Forced expiratory volume in 1s (FEV₁)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Freedom from bronchiolitis obliterans syndrome (BOS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Adverse reactions reported by patients
Endpoint domain: Adverse events/effects
Primary endpoint: serum level of triglyceride
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Low birth rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Regular menstrual cycle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Severe menopausal symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: PCO2 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximal hyperaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CIBIC+ scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in early EPCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in peripheral arterial tone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in homocysteine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: exchangeable zinc pool masses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: HDL(2) cholesterol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 12-month typical use failure rates
Endpoint domain: Mortality/survival
Primary endpoint: 12-month cumulative consistent-use failure rates
Endpoint domain: Mortality/survival
Primary endpoint: N100 component amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: total weight gain at the end of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Colonic spasm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Procedure difficulty
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Medication adherence improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: burst frequency of muscle sympathetic nerve activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Life Attitude Profile score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: General Symptom Inventory score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: 10m walking test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BBT (Berg Balance Test)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FR (Functional Reach)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of HIV acquisition
Endpoint domain: Mortality/survival
Primary endpoint: percentage of slow-wave sleep
Endpoint domain: Physiological/clinical
Endpoint subdomain: Sleep
Primary endpoint: attention improvement
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: WMH density in lobes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: STI testing frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: self-reported total physical activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: objectively measured physical activity level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage increase in low-density lipoprotein cholesterol (LDLc)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Composite outcome rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: mean decrease in nausea visual analog scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection rate of UUT-TCC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of PDD-FURS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of PDD-FURS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: KMI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: potassium supplementation requirements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: urinary potassium losses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Recovery after targeted treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Posttreatment pain intensity on activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HIV-related kidney complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: blood lactate clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glycemic control (HbA₁c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: calories per transaction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes